Showing results (1451-1460 of 1,560) with videos related to

Sort By:
Pageof 156
Journal of Cardiovascular Electrophysiology|April 29, 2025
Genome-Wide Association Study of Atrial Fibrillation Recurrence After Radiofrequency Catheter Ablation in a Japanese PopulationTakumi Sakai, Motoki Furutani, Mika Nakashima, et al.
Journal of Biomedical Science|December 9, 2016
Genetic variations of aldehyde dehydrogenase 2 and alcohol dehydrogenase 1B are associated with the etiology of atrial fibrillation in JapaneseYukiko Nakano, Hidenori Ochi, Yuko Onohara, et al.
Scientific Reports|February 9, 2017
Intestinal cancer stem cells marked by Bmi1 or Lgr5 expression contribute to tumor propagation via clonal expansionHirotsugu Yanai, Naho Atsumi, Toshihiro Tanaka, et al.
Heart Rhythm|July 20, 2026
Genome-Wide Identification of a MINK1 Variant Associated with Asymptomatic Paroxysmal Atrial FibrillationSho Okamura, Motoki Furutani, Mika Nakashima, et al.
Surgical Case Reports|October 23, 2024
An aggressive gastric CIC-DUX4 sarcoma surgically resected with multivisceral organs: a case reportMizuki Koba, Atsushi Takeno, Hiroko Hasegawa, et al.
Scientific Reports|September 2, 2017
Intestinal stem cells contribute to the maturation of the neonatal small intestine and colon independently of digestive activityHirotsugu Yanai, Naho Atsumi, Toshihiro Tanaka, et al.
JACC. Advances|May 29, 2026
Genetic Variants Associated With Nonpulmonary Vein Triggers of Atrial Fibrillation: A Genome-Wide Association StudySho Okamura, Motoki Furutani, Mika Nakashima, et al.
Gynecologic Oncology|March 12, 2019
The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1)Ryusuke Murakami, Noriomi Matsumura, Hirofumi Michimae, et al.
Plos One|April 2, 2013
Genetic structure of wild bonobo populations: diversity of mitochondrial DNA and geographical distributionYoshi Kawamoto, Hiroyuki Takemoto, Shoko Higuchi, et al.
The Lancet. Oncology|December 16, 2019
Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialHironobu Hashimoto, Masakazu Abe, Osamu Tokuyama, et al.
Pageof 156